Kurabo Industries will acquire 21.6 million shares of TOWNS, an in vitro diagnostics manufacturer, making it an equity-method affiliate, and will enter into a capital and business alliance agreement. The acquisition price is ¥13.340 billion, and the acquisition is scheduled to be completed on 30 November.
Kurabo Industries announced that it will acquire 21.6 million shares of TOWNS, an in vitro diagnostic products company, through an off-market negotiated transaction, making TOWNS an equity-method affiliate. Following the acquisition, its voting rights holding in TOWNS will be approximately 20.27%, and the total amount to be paid by Kurabo Industries to acquire the TOWNS shares is reported to be ¥13.340 billion. The acquisition is scheduled to be completed on 30 November 2026, with the formal procedures expected to be completed on the same date. Trustar Capital Japan Partners III, L.P. and 2 other parties are also involved.
In addition to entering into a capital and business alliance agreement, the 2 companies plan to pursue the development of new products and services through joint research and development and the mutual use of technology and facilities in the life sciences field, cooperation in domestic and overseas markets, and personnel exchanges. Kurabo Industries expects to expand its sales platform by leveraging TOWNS's sales network for medical institutions and testing facilities, while TOWNS expects to enhance its research and development capabilities by drawing on Kurabo Industries' gene extraction and analysis technologies.